Who can take part?

You, or someone you care for, may be able to take part if you/they:

- are 30-80 years of age
- have been diagnosed with T2DM and CKD
- do not require kidney dialysis.





What else do I need to consider?

- The study team will explain the possible benefits and risks of the study.
- You do not have to take part in the study if you don't want to.
- If you choose to take part in the study, you can stop participating at any time.
- You may be paid to take part in this study and you may be reimbursed for study-related travel costs.
- All study treatments and study-related tests will be provided at no cost to you.
- A team of doctors and nurses will monitor your health carefully during the study.

How do I get more information?


To find out more about the *proact* study, contact the study team using the information provided here. Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.

Contact Us:
Cesar Barrera or Greg Lyons
cbarrera@ummc.care or glyons@lfros.com
Phone: (281) 513-3360 or (832) 659-4042
or contact us at
research@lfros.com

www.lfrosresearch.com



Patient Brochure, 30 Aug 2022 [V04 USA(en)]



What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about an investigational product or therapy, such as:

- Does it work?
- How safe is it?
- Are there side effects?

All medications and medical therapies must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications or medical therapies.

Deciding to take part in a clinical research study is your decision.

If you have any questions, you can contact the study team using the information provided in this brochure.

About the *proact* study

The *proact* study is looking at an investigational product for people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), called Renal Autologous Cell Therapy (REACT). The investigational product is made using a person's own kidney cells from tissue collected by kidney biopsy.

The study will see if the investigational product is safe and whether it works to improve function in kidneys damaged by T2DM.

What will the *proact* study involve?

If you take part, you will be in the *proact* study for up to 5 years. You will:

- visit the study center at least 13 times in the first 6 months of the study (this may include 2 overnight stays)
- have 1 telephone follow-up visit
- have follow-up visits at the study center every 3 months until the study ends.

You will be assigned to 1 of 2 study groups by chance (like flipping a coin). One study group will undergo a biopsy and receive 2 injections of the investigational product. The other study group will undergo a simulated (fake) biopsy, (no tissue will be collected) and receive 2 simulated (fake) injection procedures (nothing will be injected into or around the kidney).

The study is made up of 7 parts:



Screening period (up to 60 days)

To see if the study is suitable for you.

Biopsy visits

You will have either a kidney biopsy or a simulated biopsy.



Study injection 1

(12 weeks after the biopsy)

You will visit the study center to receive either the first injection of the investigational product or the first simulated injection.



Follow-up period 1

(3 months)

There will be 4 follow-up visits after the first injection of the investigational product or the first simulated injection.



Study injection 2

(3 months after the first study injection)

You will visit the study center to receive either the second injection of the investigational product or the second simulated injection.



Follow-up period 2

There will be up to 3 follow-up visits after the second injection of the investigational product or the second simulated injection.



Long-term follow-up period (until the study ends)

There will be long-term follow-up visits every 3 months. These will start 6 months after the first study injection and continue until the study ends.